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Abstrak
Latar Belakang: Vaksinasi merupakan salah satu cara efektif dalam mengontrol dan mengurangi beban penyakit 
yang disebabkan oleh Influenza. Akan tetapi, efikasi vaksin bisa bervariasi jika strain yang digunakan untuk vaksin 
berbeda dengan strain yang bersirkulasi di dunia. Hal ini menunjukan pentingnya melakukan analisa prediksi 
efikasi vaksin. Pada studi ini, prediksi efikasi vaksin Influenza A/H3N2 dilakukan berdasarkan perhitungan antigenic 
distance strain vaksin WHO dengan virus influenza yang berasal dari jemaah Haji Indonesia pada tahun 2013.
Metode: Sekuensing gen HA dilakukan terhadap dua sampel tersimpan yang terkonfirmasi positif Influenza A/
H3N2 yang berasal dari jemaah Haji Indonesia tahun 2013. Pepitope Calculator digunakan untuk menghitung 
antigenic distance dari dua strain virus influenza dan dilanjutkan dengan perhitungan Pepitope value. Vaksin strain 
yang direkomendasikan oleh WHO; A/Texas/50/2012, A/Switzerland/9715293/2013, A/HongKong/4801/2014 
dan dua virus yang diambil dari jemaah Haji Indonesia pada tahun 2013 dianalisa pada studi ini.  
Hasil: Prediksi efikasi vaksin yang direkomendasikan WHO tahun 2013 (A/Texas/50/2012) dengan sampel 
yang berasal dari jemaah Haji Indonesia tahun 2013 menunjukkan hasil lebih rendah dibandingkan dengan 
strain vaksin untuk musim flu pada tahun selanjutnya. Hasil ini sesuai dengan hasil analisis filogenetik 
dan perbandingan asam amino dimana sampel pada studi ini berkerabat lebih dekat dengan strain vaksin 
untuk musim flu selanjutnya dengan perbedaan asam amino yang lebih sedikit di bagian epitope protein HA 
dibandingkan dengan vaksin tahun 2013. 
Kesimpulan: Perhitungan efikasi vaksin menggunakan antigenic distance antara strain vaksin WHO dan virus 
yang menginfeksi jemaah haji Indonesia pada tahun 2013 menunjukkan hasil yang rendah. (Health Science 
Journal of Indonesia 2018;9(1):1-7)
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Abstract
Background: Influenza vaccination is an effective approach to control and reduce the disease burden of 
influenza viruses. However, the efficacy of influenza vaccine varies every year due to the different antigenic 
distance between vaccine and the circulating influenza strains globally and therefore necessitates the study 
of vaccine efficacy (VE). This study describes the prediction of Influenza A/H3N2 VE based on antigenic 
distances WHO vaccine strains and the virus obtained from Indonesian Hajj pilgrims in 2013.
Methods: Coding between Sequence of HA gene of Influenza A/H3N2 virus was obtained from archival 
samples of Indonesian Hajj Pilgrims in 2013. Pepitope value calculation using Pepitope Calculator to measure the antigenic 
distance of HA sequences of two influenza strains was implemented. The HA sequences of WHO vaccine strains: A/
Texas/50/2012, A/Switzerland/9715293/2013, A/HongKong/4801/2014 and two influenza viruses from Indonesian 
Hajj pilgrims in 2013 were analyzed.
Results: This study predicted that influenza vaccine strain recommended by WHO for 2013 (A/Texas/50/2012) have 
low efficacy to the influenza virus obtained from Indonesian Hajj Pilgrim in 2013 while showing higher efficacy to 
vaccine strain recommended for the following year. This result was in line with phylogenetic analysis and amino acid 
differences in which the samples in this study were grouped together with vaccine strain in following years and had 
less amino acid differences in epitope located in HA protein compared with 2013 vaccine strain.
Conclusion: The prediction of VE using the antigenic distance measurement between WHO vaccine strain and 
Indonesian Hajj pilgrim collected in 2013, is considered low. (Health Science Journal of Indonesia 2018;9(1):1-7)
Keywords: Vaccine efficacy, influenza A/H3N2 virus, Hajj pilgrim, Indonesia
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The Influenza virus has become a global public 
health concern as million cases with mild to severe 
respiratory syndromes and approximately half a 
million death worldwide were reported annually.1 
The natural characteristics of Influenza A virus with 
its segmented RNA genome emphasizes the rapid 
viral evolution. The Influenza virus has a potential 
being a global threat in the form of Influenza epidemic 
and pandemic due to the sequential accumulation of 
genetic and antigenic changes overtime.2, 3 
Vaccination is believed to be an effective approach 
to control and reduce the disease burden caused by 
influenza viruses.4 However, there are variations 
on the efficacy of influenza vaccine from year to 
year due to the different antigenic distance between 
vaccine and the circulating influenza strains.5, 6 The 
selection of component strains for annual influenza 
vaccine is essential as the recommended viral strains 
should offer optimal immunity from numerous 
variants of influenza virus in global circulation. The 
main focus of genetic and antigenic surveillance is 
on haemagglutinin (HA) since the antibodies to other 
protein such as Neuraminidase (NA) were reported 
not to have neutralizing ability toward Influenza 
virus infection.7 Hence, the official recommendation 
for influenza vaccine formulations should be based 
on the HA gene of global circulating influenza 
strains.4, 8
The roles of mass gathering events such as Hajj 
pilgrimage in the transmission of infectious diseases 
have been described in several publications.9, 10 Since 
influenza viruses can spread rapidly, the possibility 
of new emerging influenza virus strains spreading 
to countries across the globe is alarming. This 
likelihood event highlights the need to vaccinate 
the pilgrims before they leave their own country. 
Ministry of Health Republic of Indonesia, suggests 
the administration of influenza vaccine to Indonesian 
hajj pilgrims. The problem arises when the influenza 
vaccine strain received by Hajj pilgrims in their 
country is different to the circulating strain in 
Kingdom of Saudi Arabia (KSA) during the pilgrim 
season. In fact, such mismatch often happened as the 
influenza viruses undergo antigenic changes, causing 
several times reformulation of vaccine composition11 
and has been described comprehensively in a recent 
study.12 
To investigate the mismatch possibility, we conduct 
a study on specimens obtained from Indonesian 
Hajj pilgrims in 2013 with influenza-like illness 
(ILI) symptoms and get hospitalized during or after 
the Hajj pilgrimage. This study has objective to 
predict the Vaccine Efficacy (VE) of Influenza A/
H3N2 vaccine based on antigenic distances between 
WHO vaccine strains and virus obtained from Hajj 
pilgrims in 2013 that had ILI symptoms after they 
have arrived in Indonesia.
METHODS
Ethical Declaration
This study has been approved by the ethics committee 
of National Institute of Health Research and 
Development number LB.02.01/5.2/KE.082/2015.
Population study and sampling strategy
The samples used in this study were archival clinical 
specimens (nasal swabs or tracheal swabs) of 
Indonesian Hajj Pilgrims with ILI symptoms in 2013. 
A total of two samples were confirmed as positive for 
Influenza A/H3N2 virus; 13015 and 13087,  using 
real-time RT-PCR by Virology laboratory, NIHRD, 
Jakarta, following the WHO protocols.13 The samples 
were suspended in Hank Balance Salt Solution (HBSS) 
transport medium and stored properly in -80°C.
RNA isolation and RT-PCR
Viral RNA was extracted directly from 140 µL of 
samples using QIAmp Viral RNA Mini Kit (Qiagen, 
Hilden, Germany) according to the manufacturer’s 
instruction. Archived clinical samples with a volume 
less than 140 µL were excluded from the study. 
Reverse transcription and amplification of complete 
coding DNA sequence (CDS) of HA gene was 
conducted using SuperScriptTM III One-Step RT-
PCR System with Platinum Taq DNA Polymerase 
(Invitrogen, Carlsbad, CA) as described previously.14 
 
Direct sequencing 
PCR products which purified using QIAquickTM 
PCR Purification Kit (QIAGEN, Hilden Germany) 
then sequenced using Big Dye Terminator V.3.1 
Cycle Sequencing Ready Reaction Kit (Applied 
Biosystem, Foster City, CA), as described by the 
manufacturer. After purification using Big Dye X 
Terminator Purification Kit (Applied Biosystems, 
Foster City, CA), the reactions were resolved in an 
automatic sequencer ABI-Prism 3130xl Genetic 
Analyzer (Applied Biosystems Foster City, CA). 
The nucleotide sequences were edited and assembled 
using Sequencer version 5.2.4. 
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Antigenic Distance 
The vaccine strain and the circulating strain’s antigenic 
distances are the input for the vaccine efficacy predic-
tion. The specific measure of antigenic distance between 
two influenza strains was calculated as Pepitope value by 
the method described in previous studies.6, 15 Pepitope value 
was defined as the fractional change of mutated amino 
acid between the epitope of one strain compared to the 
vaccine strain, as shown in equation below.6, 16
It is assumed that an antigenic epitope which has the 
greatest percentage of mutations is the dominant epitope, 
because it is influenced by the greatest selective pressure 
from the immune system. The HA1 domain of H3 virus 
contains five non-overlapping epitopes, namely epitopes 
A (amino acid position 140-146), B (amino acid position 
155-160, 188-198), C (amino acid position 276-281), 
D (amino acid position 204-220) and E (amino acid 
position 170-174, 259-265).17 The dominant epitope is 
defined as the epitope with the greatest Pepitope value. 
Pepitope Calculator, a Microsoft Excel-based file, was 
applied for H3 sequence and used to calculate Pepitope 
value between WHO vaccine and Indonesian viruses.6, 16 
This study used vaccine strains obtained from GISAID: 
A/Texas/50/2012 (accession number EPI377499), A/
Switzerland/9715293/2013 (accession number EPI-
530687), A/HongKong/ 4801/2014 (accession num ber 
EPI539576), the recommended vaccine in 2013 to 2016, 
respectively. 
Based on the Pepitope Calculator output, the dominant 
epitope with the greatest Pepitope value and the amino 
acid discrepancies between two influenza viruses 
were obtained to analyze the antigenic distance.
Vaccine Efficacy (VE)
The antigenic distance between vaccine and the circulating 
strains correlates well with the influenza vaccine efficacy. 
Thus, the vaccine efficacy can be predicted by calculating 
the antigenic distance (as Pepitope value).
5, 18 The quantitative 
definition of the correlation of Pepitope and VE is given by E= 
-2.47 × Pepitope + 0.47. This equation predicts the vaccine 
effectiveness of 47% when Pepitope = 0 for the H3N2 virus.
6, 19
Phylogenetic analysis
Phylogenetic tree of HA gene was generated using 
Neighbor Joining in MEGA 6.0 with 1000 replicates. 
WHO vaccine strains A/Texas/50/2012, A/
Switzerland/9715293/2013, A/HongKong/4801/2014, 
and H3N2 sequences originated from Northern and 
Southern Hemispheres were included in the analysis. 
These sequences were obtained from GenBank. 
Influenza virus activity had different pattern in each 
part of the world. In Northern Hemisphere, patients 
with influenza were reported during winter season in 
December into February, while in Southern Hemisphere 
the peak of influenza activity is during winter season 
in June to August. Therefore it is necessary to include 
influenza virus collected from countries located in 




The antigenic distance followed by the prediction of 
Influenza A/H3N2 vaccine efficacy by Pepitope value 
analysis between concurrent WHO vaccine strains 
and Indonesian viruses obtained from Hajj pilgrims 
in 2013, is reported in this study. 
As described in Table 1, sample 13015 had the highest VE 
against A/Switzerland/9715293/2013 while the 13087 
had the highest VE against A/HongKong/4801/2014. 
Although both of the Indonesian H3N2 viruses 
were collected in 2013, the analysis using Pepitope 
value indicates that both samples had the higher VE 
against WHO recommended vaccine strains for 2015-
2016 (A/Switzerland/9715293/2013) and 2016 (A/
HongKong/4801/2014) seasons, respectively. 
Table 1. Vaccine Efficacy Prediction of Influenza Vaccine 
against Indonesian Influenza A/H3N2 virus 
obtained from Hajj Pilgrims




- Dominant epitope B B
- Pepitope value 0,142857143 0,142857143





- Dominant epitope A A
- Pepitope value 0,105263158 0,157894737
- VE  (%) 0.211 (21.1) 0.08 (8.0)
2016 influenza season:  A/
HongKong/4801/2014
  
- Dominant epitope B B
- Pepitope value 0,142857143 0,095238095
- VE  (%) 0.117(11.7) 0.235 (23.5)
             (Number of amino acid differences in the epitope)
P epitope value=
                   (Total number of amino acid in the epitope)
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Analysis by comparing the amino acids of the five 
epitopes (epitopes A to E) between WHO vaccine strains 
and virus from Indonesian Hajj pilgrims was performed to 
investigate the mutations occurred in these five epitopes 
(Table 2). In line with the findings described in Table 1, 
the dominant epitope in the analysis was epitope A and 
B, suggesting the amino acids discrepancies between 
WHO vaccine and influenza virus from Indonesian Hajj 
pilgrims were located in epitope A and B of HA gene. 
To support these finding, we carried out phylogenetic 
analysis of Indonesian strains together with WHO vaccine 
strains and other influenza A/H3N2 viruses from 
Northern and Southern Hemispheres. The phylogenetic 
tree of HA gene illustrated that the Indonesian Hajj 
sequences obtained in 2013 were not clustered with 
A/Texas/50/2012 but with the vaccine strains for 
the next seasons (Figure 1). Sample 13015 was 
grouped together with A/Switzerland/9715293/2013 
and sample 13087 was clustered with A/Hong 
Kong/4801/2014. The sample 13015 had the highest 
VE against A/Switzerland/9715293/2013 (21.1%) 
while the 13087 had the highest VE against A/
HongKong/4801/2014 (23.5%).
Table 2. Amino Acid Discrepancies in Epitope A to E between WHO Vaccine and Indonesian Influenza A/H3N2 viruses
Vaccine strain





















































- S96N - S144N Y159F, P194L - S96N -
Figure 1. Phylogenetic tree of HA gene of H3N2 virus. Indonesian sequences were in red while the WHO vaccine strains 
were in blue.
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DISCUSSIONS 
The instability of influenza virus genome that causes 
sequential accumulation of genetic and antigenic 
changes in the surface glycoproteins allows influenza 
virus to evade the neutralizing antibodies.20, 21 
WHO regularly monitors influenza circulating 
strains globally to determine the update genetic and 
antigenic changes within these viruses that may lead 
to Influenza vaccine reformulation.
Hemagglutinin Inhibition (HI) assay was commonly 
used as epidemiological surveys and widely used for 
estimating the efficacy of influenza vaccine as this 
method only requires patient’s serum for the assay.22 
However, this assay is laborious and needs more time 
to perform. Moreover, the antibody measured by HI 
assay could not be concluded as a result of previous 
exposure to disease or vaccination, but only correlates 
with the level of protection.23 Study using different 
vaccine types also gives different results of HI titers.24
The estimation of the antigenic distance between 
two influenza strains followed by the calculation of 
Pepitope value is a novel approach to predict the VE. 
The VE estimation by Pepitope model could be utilized 
to predict the antigenic distance based on the HA 
sequence of the virus and vaccine efficacy6. This 
method can also be an effective tool to define the 
closest vaccine strain against potential circulating 
viruses. Pepitope value calculation on the antigenic 
distance between two Influenza strains may be used 
to predict the VE of influenza vaccine strains in 
Indonesia.
Our data shows that based on the prediction using 
Pepitope value, WHO recommended vaccine strain 
for 2013 season, A/Texas/2012, has low VE against 
our samples (Indonesian Hajj pilgrims virus strains 
collected in 2013). The result suggests that the 
viruses in this study had closest amino acid similarity 
to WHO vaccine strain for the next year. This finding 
is parallel with the previous report from Indonesian 
ILI surveillance that detected antigenically drifted 
viruses similar to the WHO vaccine strains earlier 
than the date of their designation by WHO.25
As the natural hallmark of influenza virus, continuous 
and accumulation of mutations within its genome 
lead to antigenic drift and generate different 
influenza strains from the previous circulating 
strains. If the mutations located within the epitope 
of the surface glycoprotein of the virus, it will cause 
vaccine mismatching due to low VE and therefore 
necessitates yearly vaccine strain update.4, 11, 26   
The vaccine VE results in this study is limited only 
for the estimation. Experimental studies with real 
VE data using patient sera are still needed to confirm 
these results. General conclusion could not be drawn 
with only limited samples since as this study only 
used two samples. Furthermore, in depth genetic and 
antigenic study of Influenza A/H3N2 virus obtained 
from a larger number of patients could give more 
information regarding the evolution of this virus and 
the vaccine efficacy. 
Influenza A/H3N2 virus has five antigenic sites in 
the HA1 domain, namely epitope A to E. Of the five 
epitopes in HA, the epitope with highest Pepitope value 
has the biggest antigenic distance and, therefore, 
determined as a dominant epitope.6 The epidemiology 
of the important drift-variants usually display four or 
more amino acid substitutions which located at two 
or more antigenic sites of the HA1 domain of HA. 
27 In this study, the dominant epitopes were epitope 
A and B (Table 2).  The similar mutations within 
these epitopes were also reported in the comparison 
of Influenza A/H3N2 virus from Thailand and A/
Switzerland/9715293/2013.28  
The important antigenic sites that had major 
significance located within antigenic site A and 
B.  Mutations in this location may act as a key 
substitution that causing the antigenic drift. The 
antigenic drift of the circulating strains in the 2014–
2015 influenza season in the northern hemisphere has 
been reported to decrease the vaccine effectiveness.29 
The amino acid substitution at the position 128 may 
relate to the loss of an N-linked glycosylation site.30 
The amino acid differences within the antigenic site 
A position 140 to 146 in HA are the characteristics 
of antigenically distinct viruses of epidemic 
significance.30 The substitutions in more than four 
of the antibody binding sites have been predicted to 
give an antigenically different virus.27 
Phylogenetic tree analysis supported VE analysis. 
The Indonesian Influenza A/H3N2 virus was different 
with the current vaccine strains but similar with the 
next season recommended vaccine strains. The two 
vaccine strains, A/Switzerland/9715293/2013 and 
A/HongKong/4801/2014 belonged into different 
clades and Indonesian samples grouped into 
different clades although collected in the same 
years. This phenomenon may suggest the diversity 
of the Influenza A/H3N2 virus as well as the global 
circulation of this virus. 
The Hajj pilgrimage is where the Muslim all around 
the world gather in KSA and this event enhances 
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the possibility of the transmission of the respiratory 
infection including influenza among pilgrims.9, 
10 The vaccination of Hajj pilgrims is still highly 
recommended. Further study of influenza evolution 
and transmission among Hajj Pilgrims, including 
Indonesian Hajj Pilgrims over period of time  is 
needed for directing public health measures.
In conclusion, based on the prediction using the 
antigenic distance measurement against WHO 
vaccine strains and Indonesian Hajj pilgrim collected 
in 2013, the VE in this study is considered low. 
This recent study have limitations as the analysis 
was  performed in the small number of samples and 
the estimation based on the modeling calculation. 
Further invitro studies to determine the biological 
function of the recent analysis are needed.
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